Colorectal carcinoma affects 24 000 patients per year in England and Wales (OPCS, 1986) . Approximately 20% of these individuals will have advanced metastatic disea at presentation, and a further 30% will develop metastases within 5 years of the initial diagnosis. The onset of metastases is assocated with considerable morbidity, and most patients will die of disease in the ensuing 6-18 months.
The mainstay of chemotherapeutic palliation is 5-fluorouracil (5-FU). 5-FU is a pyrimidine antimetabolite acting in the 'S' phase of the cell cycle (MacMillan et al., 1978) . The cytotoxic effects of 5-FU are mediated by active metabolites which inhibit the synthesis of thymidine, DNA and proteins (Ullman et al., 1978) . The clinical effectiveness of 5-FU is schedule dependent. Bolus regimens give consistently poor results with response rates of 5-25% (Horton et al., 1970; Siefert et al., 1975; Ansfield et al., 1977; Erlichman et Lokich et al., 1989) . Response rates improve markedly when 5-FU is administered by i.v. infusion over 5 days or by protracted i.v. infusion over a period of many months (Siefert et al., 1975; Hartman et al., 1979; Lokich et al., 1981; Nobile.et al., 1988; Petrelli et al., 1988; Wade et al., 1988; Leichman et al., 1990; Poplin et al., 1991) .
In an attempt to further improve results, 5-FU has been used in combination with a number of anti-neoplastic agents including alpha interferon. Synergism of alpha interferon and 5-FU has been demonstrated in vitro in various cell lines of gastrointesinal origin, including several human colonic carcinoma cell lines . Based on these results, clinical trials have been established to evaluate the effectiveness of alpha interferon and 5-FU in colorectal carcinoma in vivo (Wadler and Wiernik 1990) . Subsequent reports of a pharmacokinetic interaction between 5-FU and alpha interferon which increases total exposure to 5-FU in vivo also provide a rational basis for the combination (Grem et al., 1991) .
The phase II trials of combined 5-FU and alpha interferon have produced encouraging results in untreated patients (response rates 26-63%), (Fornasiero et al., 1990 , Huberman et al., 1990 Kemeny et al., 1990; Pazdur et al., 1990 , Wadler et al., 1991 . Simila response rates (30-52%) have been obtained in phase II trials of an alternative regimen using a protracted continuous inusion of 5-FU as a single agent (Ausman et al., 1985; Wade et al., 1988; Lokich et al., 1989 Lokich et al., ,1991 Findlay et al., 1993) . The low toxicity recorded with this regimen prompted us to examine the feasibility and efficacy of combining continuous infusional 5-FU with alpha interferon in patients with metastatic colorectal carcinoma.
Thirty individuals with metastatic colorectal carcinoma were studied. Twehe patients had metastatic disease at the time of initial diagnosis and 18 patients had relapsed after a complete surgical clerance of apparently locahsed diseas. All patients had at least one site of bidimensionally measurable disease, were symptomatic and had a performance status of 1-3 on the WHO scale. Patients who had received no prior chemotherapy and those previously treated with interleukin 3 or interieukin 6 in phase I trials were eligible. Patients previously irradiated were included provided they had measurable disease outside the radiation field. All patients gave written informed consent and the study was Response and toxicity were recorded in accordance with the UICC criteria. A complete response was defined as a complete disappearance of all signs of active disease for a minimum of 4 weeks. A partial response required a reduction of more than 50% in the sum of the products of the large perpendicular axis of measurable lesions or a 50% decrease in evaluable lesions. Progression was defined as a more than 25% increase in the size of existing measurable lesions or the appearance of any new lesion and stabilisation if there was no change which amounted to a partial response or progression.
Standard statistical measurements were used and Kaplan-Meier curves constructed to estimate survival.
Results
All 30 patients were evaluable for response, toxicity and survival. The pretreatment characteristics of patients are shown in Table I . The median age was 54 years. Overall, 14 parients had liver metastases, five had lung metastases and seven had liver and lung metastases. Eight patients completed the planned treatment without delay. A total of 20 patients (67%) received 10 or more weeks of treatment. Nine patients were withdrawn after 2-9 weeks of treatment because of obvious progression or death, and one patient was admitted for surgical repair of a gastrocolic fistula after 6 weeks. Treatment was delayed for I or 2 weeks in eight patients and for 3 or 4 weeks in four patients. The principal reasons for treatment delay are shown in Table II .
When delays and dose reductions were taken into account. the majority of patients (20/30) received between 1.5 and 2.9 g week' over 9 -12 weeks. This was equivalent to a dose range of 101-244 mgm-2day-' 5-fluorouracil (Table III) .
The average dose was 170±23 mg m-2 day-'. Only one patient achieved the full dose of 3 gweek-'. Five patients received an average of <0.9 gweek-' over the 12 week period. In this group, treatment was stopped after 2-4 weeks because of death or progressive disease. Four patients received 1.1-1.4 gweek-1 (equivalent to [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] mgm-2day-) because treatment was curtailed by death, surgery or toxicity after 5-9 weeks. symptomatic and rapidly enter the terminal phase, whereas others may be asymptomatic or minimally symptomatic for long periods of time from the diagnosis of metastases (53-621 days in our series) and continue to have a prolonged clinical course in the symptomatic phase. Clearly, it is essential to identify reliable prognostic criteria which would aid selection of those patients most likely to benefit from early treatment and those for whom expectant treatment would be more appropriate.
Two additional factors which may have compromised our response rates are the low doses of 5-FU and alpha interferon administered. The intended dose of 5-FU in most studies using single-agent infusional 5-FU is 300 mg m-2 day-'. with dose reductions to 250-200 mg m-day' in the event of toxic effects. Our patients commenced at 2.5 gweek'. and half (15,/30) required subsequent dose reduction. The majority received an average of 1.5-2.9 gweek-'. This dose is equivalent to 101-244 mgm2 day-', and the average dose received (170 mgm2 day-1) is clearly well below the doses tolerated in other studies using 5-FU alone. The dose-limiting side-effect was oral mucositis and, to a lesser extent, nausea and diarrhoea.
Although WHO grade 3-4 mucositis did not occur, we found that persistent mild mucositis was poorly tolerated over the long treatment period and precluded subsequent dose escalations.
We used a fixed low dose of alpha interferon (3 x 106U x three times a week) with the initial intent of maximising the dose of the primary active agent, 5-FU. The clinical effect of alpha interferon on colorectal carcinoma trials does not appear to be dose related. More responses have been reported with 5-FU in combination with low doses of alpha interferon compared with high doses: five out of nine patients treated with 6 or 9 x 106U responded compared with none treated with 12, 15 or 18 x 10U x three times a week ) and 4/9 and 4/7 treated with 3 and 5 x 10U m-' daily, respectively, compared with 2/6 treated at 10 x 10% m-daily (Grem et al., 1991) . By contrast, toxic effects appear to increase with increasing doses of alpha interferon. When compared with high doses of alpha interferon, low-dose regimens (3 or 5 x 10U m-2 daily) are associated with a lower incidence of severe mucositis, CNS toxicity and a lower requirement for dose reduction of 5-FU (Grem et al., 1991) . However, the dose of 5-FU tolerated by most of our patients (101-244 mg m-2day-') was lower than that tolerated by others treated with single-agent continuous infusional 5-FU (200-300 mg m-2 day-'), suggesting that even 3 x 106U of alpha interferon three times a week may increase the toxicity of 5-FU (Lokich et al., 1989 (Lokich et al., , 1991 Wadler et al., 1991; Findlay et al., 1993) . This finding corroborates those of Meadows et al. (1991) , who reported an increase in mucositis and a low actual dose of 5-FU delivered (160 mgm-2 day-) with doses of alpha interferon in excess of 2 x 106 U m-2 three times a week in patients with gastrointestinal tumours. Similarly, in a study by Grem et al. (1991) , addition of alpha interferon reduced the maximum tolerated dose of This phenomenon may be due in part to the pharmakokinetic and biochemical interactions between the two agents. At doses of 5 and 10 x 106 U m2 day-', alpha interferon increases the total exposure of 5-FU by increasing the half-life and reducing its clearance (Grem et al., 1991) . Additional clinical and toxic effects may be due to the synergistic biochemical interaction of 5-FU and alpha interferon on the inhibition of thymidylate synthetase which has been demonstrated in preclinical studies. A recent clinical study using magnetic resonance spectroscopy to monitor the metabolism of 5-FU provides evidence for biomodulation in vivo: addition of alpha interferon increased the accumulation of 5-FU in responsive tumours and was associated with the appearance of new cytotoxic anabolites not found with single-agent 5-FU (Findley et al., 1993) .
In this study, we found no evidence of clinically beneficial chemomodulation of 5-FU by alpha interferon. However, as the continuous infusional 5-FU was extremely well tolerated and some patients may have received suboptimal doses, we plan to further assess its efficacy as a single agent given to dose-limiting toxicity over long periods of time in symptomatic patients. As a potentially large number of patients may be eligible for treatment each year, the feasibility of community-based care is being studied in parallel.
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